Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Graham R Foster

Showing results (141-150 of 191) with videos related to

Pageof 20
Sort By:
Journal of Hepatology|January 18, 2018
Reply to: "Reply to: 'Response to DAA therapy in the NHS England Early Access Programme for rare HCV subtypes from low and middle income countries'"Ana da Silva Filipe, Vattipally Sreenu, Joseph Hughes, et al.
Journal of Hepatology|August 26, 2014
Telbivudine plus pegylated interferon alfa-2a in a randomized study in chronic hepatitis B is associated with an unexpected high rate of peripheral neuropathyPatrick Marcellin, Karsten Wursthorn, Heiner Wedemeyer, et al.
Gastroenterology|May 13, 2019
Amino Acid Substitutions in Genotype 3a Hepatitis C Virus Polymerase Protein Affect Responses to SofosbuvirPeter A C Wing, Meleri Jones, Michelle Cheung, et al.
Hepatology (Baltimore, Md.)|June 30, 2015
Alisporivir plus ribavirin, interferon free or in combination with pegylated interferon, for hepatitis C virus genotype 2 or 3 infectionJean-Michel Pawlotsky, Robert Flisiak, Shiv K Sarin, et al.
Scientific Reports|February 23, 2012
An orally available, small-molecule interferon inhibits viral replicationHideyuki Konishi, Koichi Okamoto, Yusuke Ohmori, et al.
Journal of Hepatology|January 17, 2013
Limited impact of IL28B genotype on response rates in telaprevir-treated patients with prior treatment failureStanislas Pol, Jeroen Aerssens, Stefan Zeuzem, et al.
Lancet (London, England)|June 8, 2014
Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trialIra M Jacobson, Gregory J Dore, Graham R Foster, et al.
BMC Public Health|December 19, 2023
HepFREEPak: protocol for a multi-centre, prospective observational study examining efficacy and impact of current therapies for the treatment of hepatitis C in Pakistan and reporting resistance to antiviral drugs: study protocolAmbreen Arif, Aliya Hasnain, Auj Chaudhry, et al.
The Journal of Experimental Medicine|May 19, 2004
Telomere erosion in memory T cells induced by telomerase inhibition at the site of antigenic challenge in vivoJohn R Reed, Milica Vukmanovic-Stejic, Jean M Fletcher, et al.
The New England Journal of Medicine|January 17, 2014
Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1Kris V Kowdley, Eric Lawitz, Fred Poordad, et al.
Pageof 20

Showing results (141-150 of 191) with videos related to

Sort By:
Pageof 20
Journal of Hepatology|January 18, 2018
Reply to: "Reply to: 'Response to DAA therapy in the NHS England Early Access Programme for rare HCV subtypes from low and middle income countries'"Ana da Silva Filipe, Vattipally Sreenu, Joseph Hughes, et al.
Journal of Hepatology|August 26, 2014
Telbivudine plus pegylated interferon alfa-2a in a randomized study in chronic hepatitis B is associated with an unexpected high rate of peripheral neuropathyPatrick Marcellin, Karsten Wursthorn, Heiner Wedemeyer, et al.
Gastroenterology|May 13, 2019
Amino Acid Substitutions in Genotype 3a Hepatitis C Virus Polymerase Protein Affect Responses to SofosbuvirPeter A C Wing, Meleri Jones, Michelle Cheung, et al.
Hepatology (Baltimore, Md.)|June 30, 2015
Alisporivir plus ribavirin, interferon free or in combination with pegylated interferon, for hepatitis C virus genotype 2 or 3 infectionJean-Michel Pawlotsky, Robert Flisiak, Shiv K Sarin, et al.
Scientific Reports|February 23, 2012
An orally available, small-molecule interferon inhibits viral replicationHideyuki Konishi, Koichi Okamoto, Yusuke Ohmori, et al.
Journal of Hepatology|January 17, 2013
Limited impact of IL28B genotype on response rates in telaprevir-treated patients with prior treatment failureStanislas Pol, Jeroen Aerssens, Stefan Zeuzem, et al.
Lancet (London, England)|June 8, 2014
Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trialIra M Jacobson, Gregory J Dore, Graham R Foster, et al.
BMC Public Health|December 19, 2023
HepFREEPak: protocol for a multi-centre, prospective observational study examining efficacy and impact of current therapies for the treatment of hepatitis C in Pakistan and reporting resistance to antiviral drugs: study protocolAmbreen Arif, Aliya Hasnain, Auj Chaudhry, et al.
The Journal of Experimental Medicine|May 19, 2004
Telomere erosion in memory T cells induced by telomerase inhibition at the site of antigenic challenge in vivoJohn R Reed, Milica Vukmanovic-Stejic, Jean M Fletcher, et al.
The New England Journal of Medicine|January 17, 2014
Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1Kris V Kowdley, Eric Lawitz, Fred Poordad, et al.
Pageof 20